The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.

NCT01881958 | Withdrawn Phase 1

• 1 other identifier: 0224-13-HMO-CTIL
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes. The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.

Conditions

Type One Diabetes

Outcome Measures

Primary Outcomes (1)

• efficacy will be measured by comparing Hemoglobin A1c

  two years

Secondary Outcomes (1)

• Safety will be evaluated calculating number of Adverse Events.

  two years

Study Arms (1)

DiaPep277®

EXPERIMENTAL

Drug: DiaPep277®

Interventions

DiaPep277® DRUG

DiaPep277®

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Fasting C-peptide levels \>= 0.2nmol/L.
• Diagnosis of type 1 diabetes
• No pregnancies or planned pregnancies of female subjects

You may not qualify if:

• The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the Investigator, are likely to affect the subject's response to treatment or the ability to complete the study.
• The subject has a history of any kind of malignant tumor (not including basal cell skin cancer).
• The subject has clinical evidence of any diabetes-related complication that in the opinion of the Investigator would interfere with the subject's participation in and/or completion of the study.
• Subject has history of endogenous allergic reactivity:
• Severe allergic reaction or severe exacerbation of allergic asthma within 12 months prior to the Screening-Ext Visit.
• Ongoing systemic asthma treatment.
• Subjects with history of life threatening or severe allergy, re-occurrence of which cannot be ruled out based on the Investigator's judgment.
• The subject has known allergy to lipid emulsions.
• The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
• The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy or any medication that in the opinion of the Investigator might interfere with the study.
• The subject has any of the following clinically significant laboratory abnormalities:
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of the normal (ULN) at the Screening-Ext Visit.
• Total bilirubin greater than 1.3 times the ULN at the Screening-Ext Visit.
• Subjects with severe renal failure at the Screening-Ext visit (as defined by glomerular filtration rate \< 30 mL/min/1.73 m2 by Cockroft und Gault calculation • Clinically significant laboratory abnormalities, confirmed by repeat measurement, which may interfere with the assessment of safety and / or efficacy of the study drug, other than hyperglycemia and glycosuria at the Screening-Ext Visit.
• Fasting triglycerides \<1000 mg/dL (11.3 mmol/L) at the Screening-Ext Visit. Suitable medical therapy for treatment of hyperlipidemia is allowed.

Sponsors & Collaborators

• Hadassah Medical Organization: lead

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2013
• First Posted: June 20, 2013
• Study Start: January 1, 2015
• Primary Completion: January 1, 2016
• Study Completion: January 1, 2017
• Last Updated: March 6, 2018

Record last verified: 2018-03